As Fierce Pharma points out, patent expirations are a routine occurrence in the pharmaceutical world, but 2025 stands out for ...

Bayer seeks EMA approval for aflibercept 8 mg for treatment of retinal vein occlusion: Berlin Thursday, April 10, 2025, 16:00 Hrs [IST] Bayer has submitted an application to the E ...

South Korea’s pharmaceutical giant Celltrion said Thursday it has received regulatory approvals for three biosimilars in ...

In the European Union and the United Kingdom, aflibercept 8mg (Eylea HD in the US) is currently approved for neovascular ...

Berlin: Bayer has submitted an application to the European Medicines Agency (EMA) seeking approval of aflibercept 8 mg (114.3 ...

Emergen Research Logo The development of anti-VEGF therapies, which inhibit the growth of abnormal blood vessels in the retina, reduces the ...

As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like ...

The global Age-Related Macular Degeneration (AMD) Market is poised for significant expansion over the next decade, with its value expected to grow from US$ 11.31 billion in 2023 to US$ 19.72 billion ...

Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

The ranibizumab biosimilar Ongavia exhibited significantly less improvement in visual acuity and retinal thickness compared ...

Oppenheimer lowered the firm’s price target on Regeneron (REGN) to $925 from $950 and keeps an Outperform rating on the shares. The firm is ...

An add-on agent designed to boost drugs that treat age-related macular degeneration failed to show any benefit in two phase 3 ...